AVCNF - Avicanna Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.6500
+0.0700 (+4.43%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.5800
Open1.5500
BidN/A x N/A
AskN/A x N/A
Day's Range1.5500 - 1.6500
52 Week Range0.9950 - 3.5300
Volume16,990
Avg. Volume6,884
Market Cap37.767M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Avicanna Ranks Highest Amongst Global Cannabis Companies in the SAM Corporate Sustainability Assessment (CSA)
    CNW Group

    Avicanna Ranks Highest Amongst Global Cannabis Companies in the SAM Corporate Sustainability Assessment (CSA)

    TORONTO , Feb. 6, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has been rated the highest amongst global cannabis companies participating in the SAM Corporate Sustainability Assessment (CSA). The SAM Corporate Sustainability Assessment (CSA), established by RobecoSAM, is now issued by S&P Global. The 2020 Sustainability Yearbook that was published on January 30th by S&P Global, showcases the sustainability performance of some of the world's largest companies.

  • Avicanna Closes First Tranche of Private Placement
    CNW Group

    Avicanna Closes First Tranche of Private Placement

    TORONTO , Jan. 24, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (FSE:0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has closed the first tranche of an up to CAD$9,000,000 non-brokered private placement (the "Offering"). Under the first tranche of the Offering, the Company has issued an aggregate of 822,721 Units (the "Units") at a price of CAD$2.50 per Unit, for aggregate gross proceeds of approximately CAD$2.06 million . The Company has also received additional subscription agreements for an additional CAD$4 million , which it expects to close on in one or more further tranches on the same terms.

  • Avicanna Announces Appointment of Benjamin Leavenworth as Independent Director
    CNW Group

    Avicanna Announces Appointment of Benjamin Leavenworth as Independent Director

    TORONTO , Jan. 21, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the appointment of Benjamin Leavenworth to the Company's board of directors, effective immediately. Mr. Leavenworth has more than 20 years' experience in international business, with a focus on Latin America .

  • Avicanna Announces the Successful Completion of its Clinical Study Evaluating the Effect of an Emollient Cream Containing 0.5% Cannabidiol on Skin Hydration
    CNW Group

    Avicanna Announces the Successful Completion of its Clinical Study Evaluating the Effect of an Emollient Cream Containing 0.5% Cannabidiol on Skin Hydration

    TORONTO , Jan. 13, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced today its results from its first cosmetic clinical study, an open-label, randomized, passive-control study examining the impact of its Pura Earth™ topical cream containing 0.5% cannabidiol and 1% hemp oil on skin hydration. The investments that we've made in the research and development of the Pura Earth products is validated by these positive clinical results and further elevates the brand in the CBD derma-cosmetics market.

  • Avicanna Announces Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc., to Distribute Avicanna's Advanced and Evidence-based Medical Cannabis and Derma-Cosmetic Products Across Canada
    CNW Group

    Avicanna Announces Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc., to Distribute Avicanna's Advanced and Evidence-based Medical Cannabis and Derma-Cosmetic Products Across Canada

    TORONTO , Jan. 10, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced today that Medical Cannabis by Shoppers will be the exclusive Canadian distributor of the Rho PhytoTM medical cannabis and Pura EarthTM CBD derma-cosmetic product lines. Medical license holders in Canada will be able to purchase a consistent supply of Avicanna's advanced and evidence-based products starting in early-2020, including the Rho Phyto line, which includes sublingual sprays, oil drops, gels, creams, tablets and capsules.

  • Avicanna to Host Key Opinion Leader Meeting on the Use of Cannabinoids for the Treatment of Pain and Epilepsy
    CNW Group

    Avicanna to Host Key Opinion Leader Meeting on the Use of Cannabinoids for the Treatment of Pain and Epilepsy

    TORONTO , Dec. 6, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, today announced that it will host a Key Opinion Leader (KOL) meeting on the use of cannabinoids for the treatment of pain and epilepsy on December 12, 2019 in New York City . The event will feature a presentation by KOLs Hance Clarke, MD, PhD., University Health Network - Toronto General Hospital, and Amza Ali , MD, FRCP, MBA, Chief Medical Officer, Avicanna Inc., who will discuss how the use of cannabinoids can help to treat patients with severe pain and epilepsy.

  • Avicanna Receives DTC Eligibility for Common Shares on OTCQX
    CNW Group

    Avicanna Receives DTC Eligibility for Common Shares on OTCQX

    TORONTO , Dec. 5, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has obtained eligibility with the Depository Trust Company ("DTC") for its common shares listed in the United States on the OTCQX® Best Market.

  • Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group
    CNW Group

    Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group

    TORONTO , Dec. 3, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an importation and distribution agreement (the "Agreement") with Astral Health Ltd. ("Astral"), the operating subsidiary of the LYPHE Group Ltd ("LYPHE Group" or "LYPHE") to supply its cannabis-based medicinal products ("CBMPs") to patients in the United Kingdom under the MHRA 'specials' programme.

  • Avicanna's Rho Phyto Branded Products to be Available in California
    CNW Group

    Avicanna's Rho Phyto Branded Products to be Available in California

    TORONTO , Dec. 1, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) today announces that LC2019, Inc. ("LC2019"), the entity that holds a license to Avicanna's intellectual property in the United States , has advised Avicanna that it has entered into an agreement (the "License Agreement") with a subsidiary of Kings Garden Inc. ("Kings Garden"), a California based company, manufacturing the Kings Garden brand, with extensive experience in the cultivation, processing and manufacturing of high-end cannabis products, pursuant to which LC2019 will sub-license Avicanna's Rho PhytoTM brand and proprietary formulations (collectively, the "Rho Products") to Kings Garden.

  • Benzinga

    Avicanna Obtains Option To Acquire US Cannabis Operator

    Avicanna Inc. (TSX:AVCN) (OTC: AVCNF) announced Tuesday it has signed a license agreement with LC2019, Inc. under which the company will license specific proprietary formulations and brand elements to LC2019 for commercialization in the United States. “We are thrilled to secure a strategy that will allow us to enter the United States as soon as federally permissible and, in the interim, provide an opportunity for our brands and science-driven product formulations to establish themselves in one of the largest and most exciting global markets for cannabis products,” said Setu Purohit, President of Avicanna.

  • Avicanna Announces Option to Purchase Newly Formed US Cannabis Operator
    CNW Group

    Avicanna Announces Option to Purchase Newly Formed US Cannabis Operator

    TORONTO , Nov. 26, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has entered into a license agreement (the "License Agreement") with LC2019, Inc. ("LC2019") pursuant to which the Company has agreed to license certain proprietary formulations and brand elements to LC2019 for commercialization in the United States. As consideration for entering into the License Agreement, LC2019 and its shareholders have entered into a definitive option agreement (the "Option Agreement") that grants Avicanna the option (the "Option") to acquire 100 percent of the issued and outstanding shares of LC2019, with such Option to be exercisable in the event that cannabis cultivation, processing, distribution and possession‎ becomes federally legal in the United States (the "Triggering Event").

  • Benzinga

    Avicanna Trades Up On Q3 Results

    Down this line, the company posted a net loss for the quarter of CA$6.19 million versus a net loss of CA$2.07 million in the third quarter of 2018. During the third quarter, the company produced the first commercial batch of Pura Earth branded derma-cosmetic products; obtained a Health Canada cannabis research license; entered a joint venture with Sigma Analytical Services for the testing of cannabis and cannabis-based products in Colombia; signed an agreement with the University of Guelph to test the effectiveness of its products in various conditions; and added 120,000 square feet of cultivation space.

  • Avicanna Reports Third Quarter 2019 Financial Results
    CNW Group

    Avicanna Reports Third Quarter 2019 Financial Results

    During this time, we have initiated several revenue streams through our various product lines, which we expect to drive the Company's future growth. This first batch included a total of approximately 28,000 units of Pura Earth product manufactured using approximately 28 kilograms of the Company's purified cannabidiol ("CBD"). Clinical trials for Avicanna's branded derma-cosmetic line, Pura Earth, with the Centro de Atencion e Investigacion Medica CAIMED S.A.S., commenced during the quarter.

  • Avicanna Announces Voluntary Lock-Up Agreements for Key Insiders and Separation of CEO and Chairman Roles
    CNW Group

    Avicanna Announces Voluntary Lock-Up Agreements for Key Insiders and Separation of CEO and Chairman Roles

    TORONTO , Oct. 29, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, today announces that its executive officers and directors have entered into voluntary lock-up agreements to extend the term of their lock-up periods, affecting approximately 7.7 million shares. The Company also announces that Kyle Langstaff has stepped down as Vice President (Operations) and has concurrently entered into a lock-up agreement to restrict the disposition of his common shares. In addition, the Company's board of directors has separated the roles of Chairman and Chief Executive Officer.

  • Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom
    CNW Group

    Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom

    TORONTO , Oct. 24, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN)(OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. ("SMGH"), its majority owned subsidiary, has completed commercial exports of its Aureus™ brand of CBD-based products to South Africa and the United Kingdom (collectively, the "Jurisdictions"). The Aureus brand of products include an organic and sustainable line of plant-derived active pharmaceutical ingredients ("APIs") and bulk CBD formulations developed by Avicanna in collaboration with SMGH and Sativa Nativa S.A.S. ("Sativa Nativa"), which is also a majority owned subsidiary of Avicanna. These initial sales included the export of CBD isolate and 4% bulk formulation for CBD oil sublingual sprays.

  • Avicanna Announces Retail Launch of Pura Earth Derma-Cosmetics with Initial Roll-Out in Colombia
    CNW Group

    Avicanna Announces Retail Launch of Pura Earth Derma-Cosmetics with Initial Roll-Out in Colombia

    TORONTO , Oct. 21, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the retail launch of its Pura Earth™ derma-cosmetics line of CBD products, which are now available at approximately 59 high-end retail locations throughout Colombia , including Blind prestige beauty shops and Cromantic professional beauty markets. Avicanna's Anti-Aging Treatment, Anti-Aging Serum, Clear Skin Treatment and Intensive Skin Conditioning Treatment, which are the first four of the nine Pura Earth product lines, are currently available at retail. Additionally the Pura Earth line will be offered on e-commerce platforms, including Percos, Cormantic, and Blind, as well as Avicanna's own platform, which is currently dedicated to Pura Earth.

  • Benzinga

    Exclusive: Avicanna Obtains First Colombian USDA Organic Certification For Hemp Cultivation

    Avicanna Inc (TSX: AVCN) (OTC: AVCNF) said Friday its subsidiary Santa Marta Golden Hemp S.A.S. (SMGH) has acquired a United States Department of Agriculture national organic program certification from Control Union Certifications, for its hemp cultivar. It has also attained registration for extra 15 genetic strains of cannabis. This is an important milestone for the company because it has become the first producer to obtain this certification in Colombia.

  • Avicanna (TSX: AVCN) Announces Receipt of the First Colombian USDA Organic Certification for its Hemp Cultivation and Registration of 15 Additional Genetics
    CNW Group

    Avicanna (TSX: AVCN) Announces Receipt of the First Colombian USDA Organic Certification for its Hemp Cultivation and Registration of 15 Additional Genetics

    TORONTO , Oct. 18, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. ("SMGH"), a majority owned subsidiary of the Company, has obtained a United States Department of Agriculture ("USDA") National Organic Program ("NOP") certification from Control Union Certifications, for its hemp cultivar, and has obtained registration for an additional 15 genetic strains of cannabis.

  • Avicanna Announces Results of Annual General Meeting
    CNW Group

    Avicanna Announces Results of Annual General Meeting

    Avicanna Announces Results of Annual General Meeting

  • Avicanna Commences Trading on the OTCQX Market in the United States
    CNW Group

    Avicanna Commences Trading on the OTCQX Market in the United States

    TORONTO , Oct. 15, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that its common shares will commence trading today on the OTCQX® Best Market in the United States under the symbol "AVCNF". The OTCQX Best Market provides added service, value and convenience to U.S. investors, brokers and institutions seeking to trade Avicanna shares. OTCQX is OTC Markets Group's premier market for established, investor-focused U.S. and international companies.